Valuation: Novacyt

Market Cap 38.5M 44.94M 36.02M 32.97M 61.88M 4.3B 62.7M 426M 166M 2.16B 169M 165M 7.14B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 40.45M 47.23M 37.85M 34.65M 65.03M 4.52B 65.89M 447M 174M 2.27B 177M 173M 7.51B EV / Sales 2026 *
1.33x
EV / Sales 2027 * 1.24x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day+8.37%
1 week+2.51%
Current month+24.50%
1 month+18.53%
3 months-8.45%
6 months+36.50%
Current year+35.81%
1 week 0.48
Extreme 0.4765
0.56
1 month 0.42
Extreme 0.415
0.56
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Date Insider Type Main position Quantity % Market Cap.
4/23/24 Free

Chief Executive Officer

946,475 1.3401%
4/23/24 Free

Chief Financial Officer

391,645 0.5545%
4/23/24 Free

Chief Technology Officer

465,078 0.6585%
Change 5-day change 1-year change 3-year change Capi.($)
+8.37%+2.51%+12.26%-40.34% 44.94M
+0.70%+1.41%-40.77%-42.95% 631M
-7.78%-15.50%+84.50% - 341M
-12.62%-1.82%-29.43%-1.36% 137M
-5.21%-16.89%-23.53%+19.74% 71.13M
Average -3.31%-6.06%+0.61%-16.23% 245.11M
Weighted average by Cap. -3.21%-4.68%-1.66%-31.33%

Financials

2026 *2027 *
Net sales 30.52M 35.64M 28.56M 26.14M 49.07M 3.41B 49.71M 337M 132M 1.71B 134M 131M 5.67B 34.86M 40.7M 32.62M 29.86M 56.04M 3.89B 56.78M 385M 150M 1.96B 153M 149M 6.47B
Net income - -
Net Debt 1.96M 2.28M 1.83M 1.68M 3.14M 218M 3.19M 21.62M 8.43M 110M 8.57M 8.39M 363M 4.84M 5.65M 4.53M 4.15M 7.78M 541M 7.89M 53.53M 20.87M 272M 21.22M 20.76M 899M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
26-08-21 €0.5310 +8.37% 750,774
26-08-20 €0.4900 -4.48% 346,416
26-08-19 €0.5130 -5.87% 576,328
26-08-18 €0.5450 0.00% 261,279
26-08-17 €0.5450 +5.21% 879,841

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock